MA35345B1 - Proteines de liaisons a un antigene ayant une liaison accrue a fcrn - Google Patents

Proteines de liaisons a un antigene ayant une liaison accrue a fcrn

Info

Publication number
MA35345B1
MA35345B1 MA36748A MA36748A MA35345B1 MA 35345 B1 MA35345 B1 MA 35345B1 MA 36748 A MA36748 A MA 36748A MA 36748 A MA36748 A MA 36748A MA 35345 B1 MA35345 B1 MA 35345B1
Authority
MA
Morocco
Prior art keywords
binding
proteins
fcrn
antigen
increased
Prior art date
Application number
MA36748A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Michael J Molloy
Tejash Shah
Ian M Tomlinson
Ahmed Yasin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44586854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35345(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA35345B1 publication Critical patent/MA35345B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des protéines de liaison à un antigène qui se lient spécifiquement au tnf-alpha. Par exemple, l'invention concerne de nouveaux variants d'anticorps anti-tnf, tels que adalimumab, qui présentent une liaison accrue au récepteur fcrn ou une demi-vie prolongée en comparaison à adalimumab. L'invention concerne également des compositions comprenant les protéines de liaison à un antigène et des utilisations de telles compositions dans le traitement de troubles et d'une maladie.
MA36748A 2011-07-19 2014-02-12 Proteines de liaisons a un antigene ayant une liaison accrue a fcrn MA35345B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1112429.4A GB201112429D0 (en) 2011-07-19 2011-07-19 Antigen-binding proteins with increased FcRn binding
PCT/EP2012/064129 WO2013011076A2 (fr) 2011-07-19 2012-07-19 Protéines de liaison à un antigène ayant une liaison accrue à fcrn

Publications (1)

Publication Number Publication Date
MA35345B1 true MA35345B1 (fr) 2014-08-01

Family

ID=44586854

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36748A MA35345B1 (fr) 2011-07-19 2014-02-12 Proteines de liaisons a un antigene ayant une liaison accrue a fcrn

Country Status (22)

Country Link
US (1) US20130243764A1 (fr)
EP (2) EP3009450A1 (fr)
JP (1) JP2014524748A (fr)
KR (1) KR20140054085A (fr)
CN (1) CN103748110A (fr)
AU (1) AU2012285786B2 (fr)
BR (1) BR112014000341A2 (fr)
CA (1) CA2841105A1 (fr)
CL (1) CL2014000134A1 (fr)
CO (1) CO6862106A2 (fr)
CR (1) CR20140029A (fr)
DO (1) DOP2014000007A (fr)
EA (1) EA201391789A1 (fr)
ES (1) ES2600854T3 (fr)
GB (1) GB201112429D0 (fr)
MA (1) MA35345B1 (fr)
MX (1) MX2014000739A (fr)
PE (1) PE20141660A1 (fr)
PH (1) PH12014500167A1 (fr)
SG (1) SG10201601154QA (fr)
WO (1) WO2013011076A2 (fr)
ZA (1) ZA201400062B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158275A1 (fr) * 2012-04-20 2013-10-24 Abbvie Inc. Procédés de culture cellulaire pour réduire des espèces acides
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
WO2013186230A1 (fr) * 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Formulation pharmaceutique destinée à un anticorps thérapeutique
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013312300A1 (en) 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
FR2999431B1 (fr) * 2012-12-17 2016-03-18 Lfb Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
CA2894225A1 (fr) * 2012-12-17 2014-06-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
AU2013384204B2 (en) * 2013-03-14 2017-03-16 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3021833B2 (fr) * 2013-07-19 2022-03-30 Hexal Aktiengesellschaft Procédés et formulations qui permettent à la modulation de réponses immunitaires associées à l'administration d'un médicament biopharmaceutique
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
WO2015057910A1 (fr) 2013-10-16 2015-04-23 Oncobiologics, Inc. Formulations de tampon pour stabilité d'anticorps améliorée
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP2946766B1 (fr) 2014-05-23 2016-03-02 Ares Trading S.A. Composition pharmaceutique liquide
HUE029849T2 (en) * 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
MY192824A (en) * 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3250598A1 (fr) * 2015-01-28 2017-12-06 Mabxience S.A. Formulations pharmaceutiques pour des anticorps anti-tnf-alpha
WO2016189491A1 (fr) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Nouvelle formulation
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
JP6954842B2 (ja) * 2015-12-25 2021-10-27 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
EP3411401A1 (fr) 2016-02-03 2018-12-12 Oncobiologics, Inc. Formulations de tampon pour améliorer la stabilité d'anticorps
CR20180445A (es) 2016-03-14 2019-02-08 Univ Oslo Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
AU2017303205B2 (en) 2016-07-29 2024-08-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity
KR20250036943A (ko) 2016-08-02 2025-03-14 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
TWI778985B (zh) * 2016-10-20 2022-10-01 法商賽諾菲公司 抗chikv抗體及其用途
CN120392659A (zh) 2017-01-11 2025-08-01 赛特瑞恩股份有限公司 稳定的液体调配物
WO2018129713A1 (fr) * 2017-01-13 2018-07-19 杭州翰思生物医药有限公司 Procédé pour améliorer l'affinité de liaison d'un anticorps igg vis-à-vis du fcrn et prolonger la demi-vie sérique de celui-ci
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (fr) 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
EP3372241A1 (fr) * 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
KR102867311B1 (ko) * 2017-08-11 2025-10-01 리서치 디벨럽먼트 파운데이션 증강된 혈청 반감기를 위한 조작된 항체 fc 변이체
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
TW202423960A (zh) 2017-09-29 2024-06-16 日商中外製藥股份有限公司 具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑
BR112020008393A2 (pt) 2017-11-01 2020-11-03 Chugai Seiyaku Kabushiki Kaisha variante e isoforma de anticorpos com atividade biológica reduzida
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
US12565664B2 (en) * 2019-03-05 2026-03-03 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Genome-edited birds
CN115770291A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用
CN115770292A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的协同免疫及其用途
TW202330032A (zh) * 2021-11-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ｓｏｓｔ抗體醫藥組成物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
NZ576133A (en) * 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
WO2009024567A1 (fr) 2007-08-20 2009-02-26 Glaxo Group Limited Procédé de production
EP2641919A3 (fr) * 2007-11-30 2014-05-07 Glaxo Group Limited Produits de construction de liaison à un antigène
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
WO2009073805A2 (fr) * 2007-12-04 2009-06-11 Verdezyne, Inc. Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques
PL2808343T3 (pl) * 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
EP2225276B1 (fr) * 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Anticorps du tnf alpha
FR2934599B1 (fr) 2008-07-29 2012-12-21 Arkema France Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations
EP2362767B1 (fr) * 2008-10-29 2017-12-06 Ablynx N.V. Formulations de molécules de liaison d'antigène monodomaines
CA2753287A1 (fr) * 2009-02-24 2010-09-02 Glaxo Group Limited Constructions de liaison d'antigene
SG173705A1 (en) * 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
RU2560701C2 (ru) 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
US20120076787A1 (en) * 2009-05-28 2012-03-29 Peter Adamson Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
WO2011074965A1 (fr) * 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Méthodes et moyens pour contrer une activité d'un domaine fc
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations

Also Published As

Publication number Publication date
EP2734548B1 (fr) 2016-08-17
KR20140054085A (ko) 2014-05-08
ES2600854T3 (es) 2017-02-13
MX2014000739A (es) 2014-02-19
CN103748110A (zh) 2014-04-23
CO6862106A2 (es) 2014-02-10
PE20141660A1 (es) 2014-11-21
CL2014000134A1 (es) 2014-07-25
GB201112429D0 (en) 2011-08-31
DOP2014000007A (es) 2014-04-30
EP3009450A1 (fr) 2016-04-20
BR112014000341A2 (pt) 2017-02-14
WO2013011076A2 (fr) 2013-01-24
AU2012285786A1 (en) 2014-02-06
AU2012285786B2 (en) 2016-05-12
CA2841105A1 (fr) 2013-01-24
NZ618897A (en) 2016-02-26
WO2013011076A3 (fr) 2013-04-04
EA201391789A1 (ru) 2014-06-30
JP2014524748A (ja) 2014-09-25
PH12014500167A1 (en) 2019-03-22
US20130243764A1 (en) 2013-09-19
EP2734548A2 (fr) 2014-05-28
ZA201400062B (en) 2017-08-30
CR20140029A (es) 2014-03-05
SG10201601154QA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
MA34927B1 (fr) Anticorps anti-cea
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA29279B1 (fr) Molecules de liaison d'antigenes se liant au recepteur egfr, vecteurs codant pour ces molecules et leurs applications
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
TNSN07398A1 (fr) Anticorps contre la p-cadherine
MA29226B1 (fr) Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations
MA33387B1 (fr) Polypeptides et procede de traitement
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
MA38161A1 (fr) Anticorps anti-bmp-6
MA49355A (fr) Formats de récepteurs de liaison d'antigène améliorés
UA108066C2 (uk) Білки, що зв'язуються з cgrp-рецепторами людини
WO2008105886A3 (fr) Anticorps spécifiques fcgriib humanisés, et leurs procédés d'utilisation
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
EA200870274A1 (ru) ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn
WO2014114651A9 (fr) Protéines de liaison à l'antigène tnf-alpha
MA28982B1 (fr) Anticorps antagonistes de il-17
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение